Nanobiopolymer for direct targeting and inhibition of EGFR expression in triple negative breast cancer
Treatment options for triple negative breast cancer (TNBC) are generally limited to cytotoxic chemotherapy. Recently, anti-epidermal growth factor receptor (EGFR) therapy has been introduced for TNBC patients. We engineered a novel nanobioconjugate based on a poly(β-L-malic acid) (PMLA) nanoplatform...
| Published: |
|
|---|---|
| Online Access: | http://hdl.handle.net/2047/d20003210 |